Design of a superior cytokine antagonist for topical ophthalmic use
about
Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responsesIdentification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method.Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 EctodomainImprovement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model.An update on dry eye disease molecular treatment: advances in drug pipelines.Phase II drugs under investigation for allergic conjunctivitis.The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline.Corneal surface glycosylation is modulated by IL-1R and Pseudomonas aeruginosa challenge but is insufficient for inhibiting bacterial binding.Investigational drugs in dry eye disease.TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.Development of CHARMM-Compatible Force-Field Parameters for Cobalamin and Related Cofactors from Quantum Mechanical Calculations.Reduction of product-related species during the fermentation and purification of a recombinant IL-1 receptor antagonist at the laboratory and pilot scale.Therapeutic inhibitors for the treatment of dry eye syndrome.The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.
P2860
Q26992101-EA90A2DE-C54F-40B5-8138-D57D458DBF67Q35565839-DA9FFDA2-23E9-40A2-916B-A57344B0F08FQ35886682-46FB4EE0-AC63-49E0-A290-E56A686299ADQ36050556-9B4476BC-B712-451D-87D0-A3A9FCF39E50Q38207723-8CC5B2C0-017C-4025-8C2C-9BEF2D254FB8Q38234039-BA208B5C-CB1D-4C61-979B-45B191EBF4E0Q38569837-29E4C8B3-4A0F-4FE8-A58C-59E8F8FA798DQ38949337-51D109ED-AE09-48C2-866B-9756A6DE770CQ38984001-E9A09898-B0FE-4B2F-A6CF-C05288CF120DQ47138569-F66B67D1-75D6-405C-876F-C06D833A29B8Q47716175-52556977-AD02-4028-BC36-D6E22EF7B978Q47861500-531781F9-9D97-4ABA-AE9F-0F78183E7F7DQ50110517-FAC7004A-66EA-4431-A055-98E97F8280DAQ52768652-6418974F-ECDF-475F-B5AC-F0E9149D5339
P2860
Design of a superior cytokine antagonist for topical ophthalmic use
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Design of a superior cytokine antagonist for topical ophthalmic use
@ast
Design of a superior cytokine antagonist for topical ophthalmic use
@en
Design of a superior cytokine antagonist for topical ophthalmic use
@nl
type
label
Design of a superior cytokine antagonist for topical ophthalmic use
@ast
Design of a superior cytokine antagonist for topical ophthalmic use
@en
Design of a superior cytokine antagonist for topical ophthalmic use
@nl
prefLabel
Design of a superior cytokine antagonist for topical ophthalmic use
@ast
Design of a superior cytokine antagonist for topical ophthalmic use
@en
Design of a superior cytokine antagonist for topical ophthalmic use
@nl
P2093
P2860
P356
P1476
Design of a superior cytokine antagonist for topical ophthalmic use
@en
P2093
Allyson Masci
Bracken M King
Emily Schirmer
Eric S Furfine
Gregory Zarbis-Papastoitsis
Jinzhao Hou
Joseph T Kovalchin
K Christopher Garcia
Kathryn Golden
Olga Kiner
P2860
P304
P356
10.1073/PNAS.1217996110
P407
P577
2013-02-19T00:00:00Z